Stocks
ARS Pharmaceuticals, Inc.SPRY
NASDAQHealthcareBiotechnology$4.03
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company focused on developing and commercializing a nasal spray for severe allergic reactions, including anaphylaxis. Its lead product, neffy, is the first FDA-approved epinephrine nasal spray, positioning the company to capture share in the emergency allergy treatment market. Investors track SPRY for its commercial execution and potential to disrupt the auto-injector market.
52W Range: $3.81-$13.15
Congressional Interest in ARS Pharmaceuticals, Inc. (SPRY)
No congressional trades have been disclosed for ARS Pharmaceuticals, Inc. (SPRY) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading SPRY?
No congressional trades found for this stock.